Cyberonics Names Bryan D. Olin, Ph.D. Vice President, Quality

HOUSTON, May 18 /PRNewswire-FirstCall/ -- Cyberonics, Inc. (Nasdaq: CYBX)
today announced that Bryan D. Olin, Ph.D., joined Cyberonics as Vice
President, Quality, effective on May 18, 2009. Dr. Olin will lead all of the
company's quality programs.

Dr. Olin joins Cyberonics from Zeltiq Aesthetics, an aesthetics device firm in
California, where he served as Senior Director, Quality Assurance, since
October 2007. Prior to Zeltiq, Dr. Olin was employed as Executive Director,
Failure Analysis, Product Quality Services and Product Safety with Cordis
Corporation, a Johnson & Johnson company. Dr. Olin spent five years with
another Johnson & Johnson company, LifeScan, as the Manager, Statistical
Engineering; Senior Program Manager, QA; Director, Complaint Handling and QA
Laboratories; and Director, Clinical Biometrics and Complaint Management. Dr.
Olin began his business career as a Statistician for Procter & Gamble,
providing statistical support to a diverse set of internal clients in R&D and
manufacturing.

"Bryan brings substantial expertise in quality management that will be helpful
in all aspects of our regulated business, including manufacturing and product
development," said Dan Moore, Cyberonics' President and Chief Executive
Officer. "He has extensive experience with regulatory inspections and
submissions, complaint handling, CAPAs and clinical study design. We are
pleased to have Bryan joining our team to lead the global quality system and
programs."

Dr. Olin received a B.S. in Mathematics from the University of Kansas. He was
awarded a Masters of Science and his Ph.D. in Statistics from Iowa State
University. Dr. Olin served as an Adjunct Assistant Professor of Industrial
Pharmacy at the University of Cincinnati for three years.

About Cyberonics, Inc. and VNS Therapy(TM)
Cyberonics, Inc. (NASDAQ:CYBX) is a medical technology company with core
expertise in neuromodulation. The company developed and markets the Vagus
Nerve Stimulation (VNS) Therapy(TM) System, which is FDA-approved for the
treatments of refractory epilepsy and treatment-resistant depression. The VNS
Therapy System uses a surgically implanted medical device that delivers pulsed
electrical signals to the vagus nerve. Cyberonics markets the VNS Therapy
System in selected markets worldwide.

Additional information on Cyberonics, Inc. and VNS Therapy(TM) is available at
www.cyberonics.com and www.vnstherapy.com.

Contact information
Greg Browne, CFO
Cyberonics, Inc.
100 Cyberonics Blvd.
Houston, TX 77058
Main: (281) 228-7262
Fax: (281) 218-9332
ir@cyberonics.com

SOURCE Cyberonics, Inc.

Greg Browne, CFO of Cyberonics, Inc., +1-281-228-7262, fax, +1-281-218-9332,
ir@cyberonics.com